ERCC1 Expression Predicts Treatment Outcome
“We have choices, and I think that would certainly be part of the new concept and design going forward, ” he added.
<[stk 3]>Dr. Lenz agreed with an attendee that recruiting patients with esophageal and gastroesophageal cancer to randomized trials has been difficult in the past and it might therefore take many years to obtain important biomarker data. But adaptive trial designs are addressing this issue.<[etk]>
I have checked the following facts in my story: (Please initial each.)
Meeting: 3660-11
Drug names and dosages: SML jsm
Lab test values and their units: n/a na
Citation (e.g., JAMA 2008;299:785-92): n/a na
Investigators’ names and affiliations: SML jsm
All other proper names (e.g., clinical trials; geographic, company, and test names): SML jsm
Investigators’ conflicts of interest and sponsor of study: SML jsm
Please provide your best contact number and email for questions on this story: (206) 393-2459; slondon@speakeasy.net
Notes:
(1) Abstract 2; log in on main ASCO page first -- https://www.asco.org
username: gi_pressaccess
password: pre$$1
Go to Virtual Meeting. Note: search function for this meeting is not working well yet, so better to look by track.
(2) Either they did not show the conflicts of interest slides at the start of the session or they blew through them at lightspeed. I don’t have any photos of them and they are not up on the Web site. So Dr. Lenz’s conflicts come from a slide in Dr. Bohanes’ talk, where the nature of the conflicts was not given.
“I think we are incorporating now more technologies with the design, which may be more flexible to adapt new findings so that we are not stuck for the next 3 or 5 years to a trial because of low accrual,” he said.
Dr. Bohanes reported that he had no relevant conflicts of interest.
Dr. Lenz reported having relationships with Response Genetics Inc. and with Sanofi-Aventis, manufacturer of oxaliplatin (Eloxatin).
